Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board

Concr announced that it has expanded its advisory board by adding former senior executives from AstraZeneca and the Cancer Research Institute.5

The new advisors bring extensive oncology, immuno‑oncology, and translational medicine experience, which Concr intends to leverage to guide its cancer-focused strategy and partnerships.5

By appointing ex‑AstraZeneca leadership, Concr aims to strengthen its pharmaceutical development, clinical strategy, and large‑pharma partnering capabilities.5

The former Cancer Research Institute executive is expected to support Concr in immuno‑oncology, research collaborations, and nonprofit/academic partnering, broadening its network across the cancer research ecosystem.5

Concr frames these appointments as a move to accelerate cancer pipeline development and platform adoption, positioning the company for its next phase of growth in oncology.5

Sources:

5. https://pharmaphorum.com/rd/changing-faces-board-directors-and-advisory-boards-october-2025